Cerity Partners
ALDX icon

Cerity Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Cerity Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Sell
72,712
-8,511
-10% -$14.6K ﹤0.01% 3124
2026
Q1 		$137K Buy
81,223
+30,174
+59% +$132K ﹤0.01% 2972
2025
Q4 		$264K Sell
51,049
-9,307
-15% -$47.8K ﹤0.01% 2481
2025
Q3 		$315K Buy
60,356
+23,779
+65% +$124K ﹤0.01% 2247
2025
Q2 		$140K Buy
+36,577
New +$94.6K ﹤0.01% 2431

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Cerity Partners's ALDX Position: Q2 2026 in Review

Cerity Partners reduced its Aldeyra Therapeutics (ALDX) stake by 10% in Q2 2026, selling an estimated $14.6K and leaving 72,712 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #3124.

Cerity Partners first reported a position in ALDX in Q2 2025 and has held it in 5 quarters since. The position peaked at $315K in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Cerity Partners held 72,712 shares of Aldeyra Therapeutics worth $155K as of Q2 2026.
  • Cerity Partners sold 8,511 Aldeyra Therapeutics shares in Q2 2026, an estimated $14.6K.
  • Aldeyra Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3124 holding.
  • Cerity Partners first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Aldeyra Therapeutics position peaked at $315K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.